Find information on Marijuana Abuse diagnosis, including clinical documentation, ICD-10-CM codes (F12.10, F12.11, F12.20, F12.21, F12.90, F12.91), DSM-5 criteria, substance use disorder treatment, and healthcare resources. Learn about cannabis use disorder, marijuana dependence, and withdrawal symptoms for accurate medical coding and billing. Explore evidence-based practices for diagnosis and intervention of cannabis-related problems in healthcare settings.
Also known as
Cannabis abuse
Harmful cannabis use, but not yet dependence.
Cannabis dependence
Cannabis addiction with withdrawal symptoms.
Cannabis use, unspecified
Cannabis use where abuse or dependence is unclear.
Tobacco use
May be relevant if used concurrently with marijuana.
Follow this step-by-step guide to choose the correct ICD-10 code.
Is marijuana use causing clinically significant impairment or distress?
Yes
Is it mild, moderate, or severe?
No
Do NOT code marijuana abuse. Consider other diagnoses or Z codes if applicable.
When to use each related code
| Description |
|---|
| Marijuana Abuse |
| Cannabis Use Disorder |
| Cannabis Intoxication |
Coding lacks specificity (e.g., dependence vs. abuse, continuous vs. episodic) impacting reimbursement and data accuracy. Relevant for medical coding, CDI, and healthcare compliance.
Failure to capture co-occurring mental health or substance use disorders may lead to underreporting severity and missed CC/MCC capture for accurate DRG assignment.
Insufficient documentation to support the diagnosis can lead to audit denials and compliance issues. CDI specialists play a key role in ensuring accurate documentation.
Q: How to differentiate between recreational marijuana use and a clinically significant Marijuana Use Disorder in adolescent patients presenting with behavioral changes?
A: Differentiating between recreational marijuana use and a diagnosable Marijuana Use Disorder (MUD) in adolescents requires a thorough assessment focusing on the frequency, quantity, and consequences of use. While experimentation is common, MUD is characterized by a problematic pattern of use leading to clinically significant impairment or distress. Look for signs like increased tolerance (needing more to achieve the same effect), withdrawal symptoms (irritability, anxiety, sleep disturbance upon cessation), unsuccessful attempts to cut down, neglecting other activities in favor of marijuana use, and continued use despite negative consequences (academic problems, relationship issues, legal trouble). The DSM-5 criteria offer a structured framework for diagnosing MUD. Consider implementing standardized screening tools like the CRAFFT or the ASSIST to aid in assessment and quantify the severity of the disorder. Explore how incorporating motivational interviewing techniques can enhance engagement and facilitate behavior change in these patients.
Q: What are the evidence-based pharmacological and non-pharmacological treatment options for managing Marijuana Use Disorder in primary care settings, considering patient comorbidities and potential drug interactions?
A: Currently, there are no FDA-approved medications specifically for treating Marijuana Use Disorder (MUD). However, off-label use of certain medications, such as N-acetylcysteine (NAC), may be considered for managing cravings and withdrawal symptoms, particularly in patients with co-occurring anxiety or depressive disorders. Non-pharmacological interventions remain the cornerstone of MUD treatment in primary care. Cognitive Behavioral Therapy (CBT) helps patients identify triggers, develop coping skills, and modify problematic thought patterns related to marijuana use. Contingency Management (CM), which reinforces abstinence with positive rewards, has also shown promising results. When selecting treatment options, carefully consider patient comorbidities and potential drug interactions. For instance, patients with psychosis or cardiovascular issues may require closer monitoring. Learn more about integrated treatment approaches that address co-occurring mental health and substance use disorders to optimize outcomes.
Patient presents with symptoms consistent with a diagnosis of Marijuana Abuse (cannabis use disorder), fulfilling DSM-5 criteria for a mild substance use disorder. The patient reports a problematic pattern of cannabis use leading to clinically significant impairment or distress, as manifested by two or more of the following within a 12-month period: cannabis is often taken in larger amounts or over a longer period than was intended; there is a persistent desire or unsuccessful efforts to cut down or control cannabis use; a great deal of time is spent in activities necessary to obtain cannabis, use cannabis, or recover from its effects; craving, or a strong desire or urge to use cannabis; recurrent cannabis use resulting in a failure to fulfill major role obligations at work, school, or home; continued cannabis use despite having persistent or recurrent social or interpersonal problems caused or exacerbated by the effects of cannabis; important social, occupational, or recreational activities are given up or reduced because of cannabis use; recurrent cannabis use in situations in which it is physically hazardous; cannabis use is continued despite knowledge of having a persistent or recurrent physical or psychological problem that is likely to have been caused or exacerbated by cannabis; tolerance, as defined by either a need for markedly increased amounts of cannabis to achieve intoxication or desired effect or a markedly diminished effect with continued use of the same amount of the substance; and withdrawal, as manifested by either the characteristic withdrawal syndrome for cannabis or cannabis is taken to relieve or avoid withdrawal symptoms. Patient reports using cannabis approximately three times per week for the past year. The patient acknowledges difficulty controlling their cannabis use and reports experiencing cravings. Patient denies significant withdrawal symptoms upon cessation. No reported instances of cannabis-induced psychosis or other significant mental health complications. Patient’s physical examination was unremarkable. Assessment includes substance use disorder screening, mental health assessment, and motivational interviewing. Plan includes brief intervention, referral to substance abuse counseling, and monitoring for treatment adherence and progress. ICD-10 code F12.10, Unspecified Cannabis-Related Disorder, is documented for billing and coding purposes. Follow-up scheduled in two weeks to assess treatment response and address any further concerns.